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PEGYLATED FILGRASTIM (PF) AFTER HIGH DOSE CHEMOTHERAPY
(HDC) AND AUTOLOGOUS STEM CELL TRANSPLANT (ASCT)
Jagasia, M.H., Greer, J.P., Kassim, A., Mineishi, S., Morgan, D., Ruffner,
K., Schuening, F. Vanderbilt University Medical Center, Nashville, TN
PF (6 mg ﬁxed dose) is equivalent to daily ﬁlgrastim (5 mcg/kg
daily for 14 days) after standard dose chemotherapy in decreasing
the duration of severe neutropenia. Daily ﬁlgrastim (5 mcg/kg)
started within 1-4 days after HDC and ASCT leads to signiﬁcant
decrease in time to neutrophil engraftment (NE). The role of PF
after HDC and ASCT is not known. We propose to study the role
of PF given as a single ﬁxed dose (6 mg) subcutaneoulsy on day 1
after stem cell infusion. Nine patients undergoing HDC and
ASCT using peripheral blood stem cells for multiple myeloma or
lymphoma have been enrolled in an ongoing study. Stem cells were
collected with peripheral blood pheresis after cyclophosphamide (3
g/sq.m) and daily ﬁlgrastim (10 mcg/kg). All patients were eligible
for HDC and ASCT as per institutional criteria and signed an
informed consent. High dose melphalan (200 mg/sq.m) was used
for patients with myeloma. Patients with lymphoma received cy-
clophosphamide (7200 mg/sq.m), BCNU (400 mg/sq.m) and in-
fusional etoposide (2400 mg/sq.m) as their conditioning regimen.
Patients received standard antiinfective prophylaxis per institu-
tional guidelines with acyclovir, levoﬂoxacin and ﬂucanozole start-
ing at day -1. Packed red blood cells (PRBC) were administered for
a hematocrit of less than 25%. Platelets were given for a count of
less than 20,000 thousand/micro.L. There were no adverse events
attributable to PF in these 8 patients. All patients engrafted neu-
trophils and platelets. There were no deaths on study in patients
who received PF. The median time to NE was 10 days (range,
8-11). Incidence of febrile neutropenia was 44% (4/9). Twenty-six
bacterial blood cultures were obtained for febrile episodes or a
suspected line infection, with only 8 (in 5 patients) being positive,
all for coagulase negative staphylococcus. Antibiotics other than
for prophylaxis were required in 56% (5/9) of patients. Antifungals
other than for prophylaxis were not required in any patient. The
median time to platelet engraftment was 17 days (range, 14-19).
The median numbers of transfusions were 3 units of PRBC and 12
units of platelets. The median numbers of days with mucositis and
total parentral nutrition were 3 (range, 0-9) and 3 (range, 0-12),
respectively. Based on this preliminary data, PF at a ﬁxed dose of
6 mg subcutaneoulsy administered on day 1 after HDC and
ASCT appears to be equivalent to daily ﬁlgrastim.
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EQUIVALENT PERIPHERAL BLOOD PROGENITOR CELL COLLECTIONS
WITH DELAYED G-CSF INTRODUCTION IN A CYCLOPHOSPHAMIDE-
CONTAINING MOBILISATION SCHEDULE
Doocey, R.T., Browett, P.J., Norcott, J., Petrasich, M., Hawkins, T.E.
Department of Haematology, Auckland Hospital, Auckland, New Zealand
The role of granulocyte-colony stimulating factor (G-CSF) in com-
bination with chemotherapy is well established in the mobilisation of
peripheral blood progenitor cells (PBPCs) for use in autologous
haematopoietic stem cell transplantation. G-CSF is usually given early
in the mobilisation schedule to allow adequate predictablity of the
optimal time for leucapharesis and to increase PBPC yield whilst
protecting against prolonged chemotherapy induced neutropenia.
There have been limited studies investigating the optimal time of
commencing G-CSF in PBPCmobilization. A later introduction may
allow cost savings from decreased G-CSF dosing without compro-
mising predictability or adequacy of PBSC collection. A prospective
analysis was performed on leucapharesis data for 50 patients (Group
A) who were mobilised with Cyclophosphamide 2 g/m2 followed by
G-CSF (Filgastrim) 5 ug/kg/day administered from Day 6 until com-
pletion of adequate CD34 cell collection. The data was compared
with a historical cohort of 50 patients (Group B) who were mobilized
on a protocol with Cyclophosphamide 2 g/m2 on Day 1 followed by
G-CSF given on Day 2. Patient characteristics were equivalent for
both groups including diagnosis, status of disease and previous cycles
of therapy. The days of G-CSF administration were signiﬁcantly
reduced in Group A as compared to Group B (6 days versus 10 days,
p  0.0001). The total dose of G-CSF per bodyweight was also
signiﬁcantly reduced in Group A (32 ug/kg versus 38 ug/kg, p 
0.007). There was no difference between the two groups in number of
leucopheresis procedures required to obtain a minimum of 2  106
CD34 cells/kg and in overall CD34 cell harvest yields. Group A
was noted to commence initial leucapharesis at one day later than
Group B (Day 12 versus Day 11, p  0.009). There were equivalent
failures of CD34 cell harvesting seen in both groups at 6%. No
mobilisation related sepsis was seen in Group A. Equivalent PBPC
yields can be obtained from the later introduction of G-CSF on Day
6 of a mobilisation schedule that commences with Cyclophosphamide
2 g/m2 onDay 1. This was achieved in our series without any increase
in failures of mobilisation or infection-related sequelae. The de-
creased growth factor consumption has beneﬁcial resource impli-
cations with a potential cost saving per patient mobilised.
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HIGH-DOSE CEB VERSUS BEAM WITH AUTOLOGOUS STEM CELL
TRANSPLANT IN LYMPHOMA
Carrier, E., Wang, E.H., Chen, Y., Castro, J., Ball, E.T., Bashey, A.,
Holman, P., Corringham, S., Lane, T. Rebecca and John Moores UCSD
Cancer Center, School of Medicine, La Jolla, CA
Medical records of 72 patients (pts) who underwent high-dose
chemo w/auto stem cell transplant (HDC-ASCT) conditioned
either CEB (cyclophosphamide 6000 mg/m2, etoposide 2000 mg/
m2, carmustine 600 mg/m2) or BEAM (carmustine 300 mg/m2,
etoposide 800 mg/m2, cytarabine 1600 mg/m2, melphalan 140
mg/m2) between 1/96 7/02 at an institution. 52 pts received CEB
20 pts received BEAM regimen. Pt characteristics include more
males (65%), age 51 years (56%), more NHL (84%) than HD,
63% w/history of complete remission (CR), 33% in CR at time of
HDC-ASCT, 54% in partial remission (PR), the remaining pts in
stable or relapsed status. Tumor grade in pts w/NHL extranodal
involvement were different between the 2 groups (p  0.02, p 
0.03 respectively). History of prior CR, status prior to ASCT were
not signiﬁcant (p  0.09, p  0.09, respectively). Regimen-related
toxicities (RRT) examined yielded diarrhea occurring at a different
frequency after treatment either CEB or BEAM (p 0.003). Cases
occurred in BEAM group (81%) than in CEB group (51%); pts
who received BEAM had milder cases (92%) than CEB (57%).
Difference in the incidence of mucositis was not signiﬁcant (p 
0.12). Pts treated with CEB developed mucositis at a slightly
higher rate (79%) than pts treated with BEAM (75%). Mucositis
occurred within BEAM group was predominately mild (67%) in
contrast to the predominance of moderate to severe cases in CEB
group (74%). All pts who required total parenteral nutrition sup-
port received CEB regimen. Pts treated w/CEB required growth
factor support for longer time than did pts treated w/BEAM (p 
0.04). Four pts (8%) in CEB group 2 pts (11%) in BEAM group
developed BCNU pulmonary toxicity, one was hospitalized. Re-
sponse rate was high in both groups, but no statistical difference
was detected (p  0.09). CEB group, 63% achieved CR 20%
achieved PR. BEAM group, 80% achieved CR and 0% achieved
PR. Survival was higher after treatment with BEAM (84%) than
CEB (60%) (p  0.09) but wasnt statistically signiﬁcant. Time to
death after HDC-ASCT occurred soon in CEB pts than BEAM pts
(p  0.09) but difference didnt reach statistical sugniﬁcance. Time
to disease progression (PD) was different between the 2 treatment
groups (p  0.03). PD occurred frequently in CEB group (38%)
than BEAM group (22%) at a faster rate (31% within 6 mo. in CEB
group versus 6% in BEAM group). Retrospective analysis, pts
conditioned w/BEAM endured less RRT had better survival than
pts conditioned w/CEB.
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OPTIMIZATION OF CHEMO-MOBILIZATION OF AUTOLOGOUS BLOOD
HEMATOPOIETIC PROGENITOR CELL GRAFTS
Hicks, M.L., Lonial, S., Langston, A., Smith, K.J., Mossavi Sai, S.,
Hamilton, E.S., Waller, E.K. Winship Cancer Institute, Emory Uni-
versity School of Medicine, Atlanta, GA
Introduction: Autologous blood hematopoietic progenitor cells
(HPCs) are typically collected by apheresis following chemother-
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apy mobilization and growth factor administration. Apheresis per-
formed on the week-end may increase resource utilization com-
pared to apheresis during the week. In order to decrease the
likelihood of week-end collections, we analyzed the timing of
apheresis with respect to chemotherapy administration and devel-
oped an optimized schedule for chemotherapy, growth factors, and
apheresis. Methods: A retrospective analysis of mobilization of
auto-grafts in 41 patients with lymphoid malignancies (NHL, MM,
HD) was performed. Chemotherapy mobilization regimes in-
cluded cyclophosphamide (n  14), CHOP, ICE, or VTEPA (n 
15), Hyper CVAD (n  8), or DT-PACE (n  4). G-CSF was
administered S.Q. once daily at a dose of 5 mcg/kg starting two
days after the last day of chemotherapy. GM-CSF was added at a
dose of 5 mcg/kg every evening starting on the 8th day after
chemotherapy. Apheresis began when the blood CD34 cells
were  20/uL. Results: The median number of CD34 cells
collected in all 66 patients was 8  10E6/kg (range 1 to 79 
10E6/kg) following a median of 2 days of apheresis. The median
number of days between the last day of chemotherapy and the ﬁrst
day of apheresis was not signiﬁcantly different between the entire
cohort of 66 patients (median 12 days, range 8-24 days) or the
subsets of patients who received cyclophosphamide (12 days),
CHOP, ICE, or VTEPA (11 days), Hyper CVAD (11 days) or
DTPACE (15 days). Among the initial 41 patients analyzed, 29%
of patients required apheresis during the week-end. Administration
of the last dose of chemotherapy on Thursday/Friday versus Tues-
day/Wednesday was associated with a reduced rate of week-end
apheresis collections (p  0.009). An optimized schedule of che-
motherapy ending on Friday was implemented in order to avoid
week-end collections and applied in 25 subsequent patients. Using
the new schema for chemo-mobilization the incidence of week-end
apheresis was reduced to 14% in the next group of 14 patients.
Among 11 patients not treated according to the new schema, the
incidence of week-end collections was 27%. Conclusion: The ﬁrst
day of apheresis can be generally predicted as occurring 11-15 days
after the last dose of chemotherapy using a combination of G-CSF
and GM-CSF treatment when these growth factors are sequentially
administered 2 and 8 days after the last dose of chemotherapy.
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IMPACT OF AGE ON OUTCOME OF AUTOLOGOUS STEM CELL TRANS-
PLANT FOR FOLLICULAR AND DIFFUSE LARGE B CELL LYMPHOMA
Arora, A., Vose, J.M., Lynch, J., Armitage, J.O., Bierman, P., Bociek,
G.R., Weisenburger, D.D. University of Nebraska Medical Center,
Omaha, NE
Incidence of Non-Hodgkins Lymphoma (NHL) rises with age.
The median age of diagnosis is 60 years. We report the impact of
age on the outcome of patients who received high dose chemo-
therapy and autologous hematopoietic stem cell transplant (HDC/
AHSCT) for follicular or diffuse large B cell lymphoma from April
1983 to June 2001. 50/484 (10%) were age 60 years with median
age of 65 years (range: 60-73). 434/484 (90%) were 60 years of
age with median age of 45 years (range 16-59). Patients 60 years
and above were more likely to have diffuse large B cell lymphoma
(84% Vs 51%, p 0.0001). Stage 3 or 4 disease was more common
in patients 60 years (32% Vs 48%, p  0.03). Other character-
istics which includes: median time from diagnosis to transplant,
number of prior chemotherapies, extranodal involvement, disease
status at transplant, LDH level and chemosensitivity did not show
any signiﬁcant differences between the two age groups. Approxi-
mately 30% of patients in each age group had received three or
more chemotherapies. Majority of the patients received BEAC/
BEAM as the conditioning regimen with peripheral hematopoietic
stem cells as the source of transplant. The median follow-up of
surviving patients was 5.9 years (range 1.5-19.2). Patients 60 years
and above had a signiﬁcantly poor 5-year event free survival rate
(27% Vs. 39%, p  0.01) and overall survival rate (31% Vs. 54%,
p  0.01) when compared to patients less than 60 years of age. On
multivariate analysis, age60 years (HR 4.4, 95% CI 1.7-11.6, p
0.01) and use of three or more chemotherapy regimens (HR 2.2,
95% CI 1.2-4.1, p  0.01) were independent risk factors for an
adverse event. Age 60 years (HR 6.5, CI 2.1-20.2, p  0.01),
female sex (HR 2.1, 95% CI 1.1-4.1, p  0.03), use of three or
more chemotherapy regimens (HR 2.9 95% CI 1.4-5.7, p  0.01),
disease resistant to chemotherapy (HR 3.5, 95% CI 1.3-9.6, p 
0.01) were independent risk factors for death. In conclusion, ad-
vanced age is a strong and independent risk factor for outcome.
AHSCT should be offered early in the course of relapse. Various
strategies that include immunotherpy and other novel treatment
are needed to improve chemoresistance in patients receiving
HDC/AHSCT.
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HIGH DOSE SEQUENTIAL (HDS) FOLLOWED BY AUTOLOGOUS BONE
MARROW TRANSPLANTATION (ABMT) AS SALVAGE TREATMENT IN
ADVANCED HODGKIN’S DISEASE (HD)
Delamain, M.T., Cardoso, R.B., Pagnano, K.B., Oliveira, G.B., Lo-
rand-Metze, I., Vigorito, A.C., Aranha, F.J.P., Eid, K.B., Miranda,
E.C.M., De Souza, C.A. Hematology and Blood Transfusion Center-
State University of Campinas-UNICAMP, Campinas, Sa˜o Paulo, Brazil
ABMT has been proposed as a salvage treatment of resistant/
refractory HD. HDS using Cy 7g/m2 for debulking and PBPC
mobilization followed by MTX 8g/m2 and then VP-16 2g/m2
before ABMT, described by Milan group, seems to be effective in
these patients. We report the results obtained using this procedure
in 31 patients with HD who failed conventional therapy or relapsed
within 24 months of conventional chemo /radiotherapy. Pa-
tients were treated with HDS followed by ABMT receiving BEAM
(BCNU, Etoposide, Ara-C and Melphalan) as conditioning regi-
men. The median age was 25 years (12-61), 20 male (64,5%) and
11 female (35,5%). The histology at diagnosis showed: 19 (61,3%)
nodular sclerosis; 9 (29%) mixed cellularity; 2 (6,5%) lymphocyte-
depleted and 1 (3,2%) lymphocyte-rich HD. Bulky disease was
presented in 15/31 (49%) patients and 6/31 (20%) had bone mar-
row inﬁltration. The Overall survival (OS) and disease free survival
(DFS) were 49% (n  31) and 60% (n  15), respectively, in 1825
days. The OS was 62% for patients with 0-1 prognostic factors at
diagnosis and a shorter OS was observed in patients with more than
2 prognostic factors (P  0.004). Bulky disease , histology type and
bone marrow involvement did not correlate with poor outcome.
Fifteen patients died, 8/15 due to progressive disease (53%), 5/15
due to toxicity after the HDS (33%) and 2/15 due to toxicity after
ABMT (13%). Status presens for alive patients after a median time
of 783 days (range 50-1929) from transplant is: CR 11 (35,5%),
partial response 2 (6,5%) and 4 in progressive disease (12,9%). We
conclude that HDS followed by ABMT is an effective salvage
regimen for patients with resistant/refractory Hodgkin’s disease
and probably induces a long and stable CR mainly in chemosen-
sitive patients. Patients presenting 2 prognostic factors at diag-
nosis presented worst outcome.
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AUTOLOGOUS STEM CELL TRANSPLANT FOR MULTIPLE MYELOMA
AND LYMPHOMA WITHOUT TRANSFUSION SUPPORT
Ford, P.A.1, Matthews, B.A.2 1. Pennsylvania Hospital, Philadelphia,
PA; 2. Pennsylvania Oncology Hematology Associates, Philadelphia, PA
High-dose chemotherapy (HDCT) and autologous peripheral
blood stem cell transplantation (APBSCT) results in signiﬁcant
anemia and thrombocytopenia with transfusion support felt to be
necessary in all patients. Our center was the ﬁrst to perform stem
cell transplantation without the use of blood products in Jehovah
Witness’s who decline transfusions based on religious convictions.
Table. Relationship Between Timing of Chemotherapy and Percentage
of Patients Pheresed on Weekends
Last Day of
Chemo Sunday Monday Tuesday Wednesday Thursday Friday Saturday
% pheresed
Saturday
or Sunday 11% 33% 44% 50% 0% 16% 25%
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